2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Shahneen Sandhu, MD, discusses the design of the phase 3 MAGNITUDE trial in metastatic prostate cancer.
Shahneen Sandhu, MD, associate professor, consultant medical oncologist, researcher, melanoma and uro-oncology units, Peter MacCallum Cancer Centre, discusses the design of the phase 3 MAGNITUDE trial (NCT03748641) in metastatic prostate cancer.
The MAGNITUDE trial assessed abiraterone acetate (Zytiga) and prednisone with or without niraparib (Zejula) in patients with metastatic prostate cancer.
Prior to enrollment, patients were screened for genetic alterations, and patients were placed in homologous recombination repair (HRR)–positive and HRR-negative cohorts, Sandhu adds. After being assigned to these cohorts, patients were then randomized to receive either study treatment.
The primary end point of the clinical trial was radiographic progression-free survival by blinded central review. Secondary end points included cytotoxic chemotherapy, time to symptomatic progression, time to PSA progression, and overall survival, Sandhu concludes.